La Jolla Pharmaceutical (LJPC) Environmental, Social & Governance (ESG) Data

Employees

Data from SEC filings

Employee count

CEO pay ratio

CEO Salary

Median Employee Salary

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Environment Hazard Materials Natural Resources Nature Offset Package Pandemic Raw Materials Wind Access Benefits Black California Consumer Privacy Act Collective Bargaining Community Culture Customer Cyber Cybersecurity Data Privacy Death Diversity Employee Engagement Gender General Data Protection Regulation Health Care Healthcare Hire Hiring Human Capital Injury Minority Privacy Recall Recruit Reimbursement Retirement Safety Satisfaction Skills Social Supplier Supply Chain Talent Union Working Condition Assessment Assurance Audit Bonus Classified Classified Board Commitment Corporate Governance Department of Director Resignation Dual-class Ethics Executive Compensation Expert Fraud Goals Hedging Incentive Independence Independent Innovation Innovative Investigation Lawsuit Leadership Litigation Long-term Majority Oversee Oversight Purpose Reputation Research and Development Responsibility Responsible Shareholder Proposals Special Meeting Strategy Supermajority Targets Tax Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On July 21, 2021, La Jolla Pharmaceutical Company (the “Company”) held its 2021 Annual Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders voted on the following proposals, which are described in more detail in the Company’s Definitive Proxy Statement on Schedule 14A that was filed with the U.S. Securities and Exchange Commission on June 4, 2021 (the “Proxy Statement”):


1.	Election of the 6 director nominees named in the Proxy Statement to serve until the 2022 Annual Meeting of Shareholders and until their successors are duly elected and qualified;


2.	Ratification of the selection of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2021; and



3.	Approval of the change of corporate domicile of the Company from California to Delaware.

Only shareholders of record at the close of business on June 1, 2021 (the “Record Date”) were entitled to vote at the Annual Meeting. At the close of business on the Record Date, 27,471,378 shares of common stock were issued and outstanding, of which 22,249,238 shares of common stock were present at the Annual Meeting, either in attendance via the live webcast or represented by proxy.

Each of the proposals voted on at the Annual Meeting was approved by the Company’s shareholders. The Company intends to consummate the change of its corporate domicile form California to Delaware in the third quarter of 2021. The final voting results with respect to each of the proposals are set forth below:

Proposal 1: Election of Directors

Name of Director Nominees
Kevin Tang	18,865,778	164,950	27,196	3,191,314
Larry Edwards	18,790,098	203,943	63,883	3,191,314
Craig Johnson	18,344,957	651,175	61,792	3,191,314
Laura Johnson	18,628,323	352,986	76,615	3,191,314
David Ramsay	18,751,517	244,921	61,486	3,191,314
Robert Rosen	18,419,900	561,167	76,857	3,191,314

Proposal 2: Ratification of Selection of Independent Registered Public Accounting Firm

For				Against				Abstain
	22,124,016				54,945				70,277

Proposal 3: Approval of Change of Corporate Domicile of the Company from California to Delaware

For				Against				Abstain				Broker Non-vote				Unvoted
	18,887,876				153,400				16,648				3,191,314				5,222,140

Additionally, holders of Series C-12 Convertible Preferred Stock (the “Preferred Stock”) were entitled to vote on Proposal 3. All 3,906 shares of Preferred Stock issued and outstanding as of the record date voted in favor of Proposal 3.